CD8A and neoplasm: Despite these remarkable clinical outcomes, a significant proportion of cancers do not benefit from Food and Drug Administration (FDA)‐approved ICB antibodies.[2] Accumulating clinical studies have shown that the lack of efficacy is correlated with a highly immunosuppressed tumor microenvironment (TME), which is characterized by the abundant presence of immunosuppressive cell subtypes together with a paucity of tumor‐infiltrating lymphocytes (primarily CD8+ T cells).